Home
|
Inbox
|
Search
|
View Abstract
The Prediction of Risk Factors of Drug-Induced Lung Complication in Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A3111 - The Prediction of Risk Factors of Drug-Induced Lung Complication in Tyrosine Kinase Inhibitor Therapy for Non-Small Cell Lung Cancer
Author Block: H. Kang; National cancer center, Goyang, Korea, Republic of.
BackgroundInterstitial lung disease (ILD) is a rare serious adverse effect of gefitinib and erlotinib. We examined the incidence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carcinoma patients treated with gefitinib or elotinib and predicted of risk factors. Methods A retrospective observational study was performed including patients who were treated with a TKI in the non-small lung cancer at National Cancer Center between January 1, 2011 and December 31, 2015. We reviewed the clinical datas including initial laboratory data of the patients, pulmoraty function test (FEV1, FEV1/FVC, and DLco/VA), CT images (ex, emphysema, fibrosis etc).And also the incidence, characteristics, the methods of treatment, and prognosis of the drug-induced lung complications were reviewed. Results In total, 1,894 patients were included (1103 for Gefitinib only, 547 for Erlotinib only, 199 for both Gefitinib and Erlotinib). Drug-induced ILD were identified in 36 patients (1.94%). The main symptom of pulmonary reaction was dyspnea, cough, but asymptomatic was also high. 11 patients (30.6%) were treated in the outpatient department, and one patient was admitted to intensive care unit. Most of them were treated with steroid. When we compared the drug-induced ILD group( 36 patients) with the non ILD group(1813 patients), the previous chemotherapy was the risk factor for ILD( p=0.025). The male patients showed lower risk to drug induced ILD risk( p=0.02) compared with female. The smoking history was high risk for the drug induced ILD( p= 0.009). According to the analysis of underline pulmonary disease (ex, emphysema, interstitial lung disease, bronchiectasis etc.), there were no correlation with the risk factor of drug related ILD. Even the chronic obstructive pulmonary disease, and DLCO level were not related with the risk factor of the drug induced pneumonitis (respectively, p=0.228 and p 0.96). ConclusionsDrug-induced ILD related TKI were related with the previous chemotherapy history, sex and smoking history in our study. And the underline lung conditions of patients were not significantly related with drug related ILD in TKI patients according to our study.
Author Block: H. Kang; National cancer center, Goyang, Korea, Republic of.
BackgroundInterstitial lung disease (ILD) is a rare serious adverse effect of gefitinib and erlotinib. We examined the incidence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carcinoma patients treated with gefitinib or elotinib and predicted of risk factors. Methods A retrospective observational study was performed including patients who were treated with a TKI in the non-small lung cancer at National Cancer Center between January 1, 2011 and December 31, 2015. We reviewed the clinical datas including initial laboratory data of the patients, pulmoraty function test (FEV1, FEV1/FVC, and DLco/VA), CT images (ex, emphysema, fibrosis etc).And also the incidence, characteristics, the methods of treatment, and prognosis of the drug-induced lung complications were reviewed. Results In total, 1,894 patients were included (1103 for Gefitinib only, 547 for Erlotinib only, 199 for both Gefitinib and Erlotinib). Drug-induced ILD were identified in 36 patients (1.94%). The main symptom of pulmonary reaction was dyspnea, cough, but asymptomatic was also high. 11 patients (30.6%) were treated in the outpatient department, and one patient was admitted to intensive care unit. Most of them were treated with steroid. When we compared the drug-induced ILD group( 36 patients) with the non ILD group(1813 patients), the previous chemotherapy was the risk factor for ILD( p=0.025). The male patients showed lower risk to drug induced ILD risk( p=0.02) compared with female. The smoking history was high risk for the drug induced ILD( p= 0.009). According to the analysis of underline pulmonary disease (ex, emphysema, interstitial lung disease, bronchiectasis etc.), there were no correlation with the risk factor of drug related ILD. Even the chronic obstructive pulmonary disease, and DLCO level were not related with the risk factor of the drug induced pneumonitis (respectively, p=0.228 and p 0.96). ConclusionsDrug-induced ILD related TKI were related with the previous chemotherapy history, sex and smoking history in our study. And the underline lung conditions of patients were not significantly related with drug related ILD in TKI patients according to our study.
|
Home
|
Inbox
|
Search
|